Research programme: psoriasis therapeutics - BioMAS
Latest Information Update: 22 Oct 2015
At a glance
- Originator Bar-Ilan University
- Developer BioMAS
- Class Organometallic compounds; Small molecules
- Mechanism of Action Integrin alpha4beta1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psoriasis